AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01098448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery, local tetracycline, systemic metronidazole and amoxicillin
Description: periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
Study NCT03973190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate alveolar regeneration after exodontia
Description: The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
Study NCT03973190 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate alveolar regeneration after exodontia
Description: The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
Study NCT03973190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: installation of dental implant and collection of biological material
Description: The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
Study NCT03973190 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: installation of dental implant and collection of biological material
Description: The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
Study NCT03973190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ISQ analysis
Description: The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
Study NCT02567266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
Study NCT03973190 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ISQ analysis
Description: The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
Study NCT02567266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
Study NCT02802345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Study NCT02802345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT02802345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02802345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study NCT02754167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRS-080#022-DP
Description: Hepcidin antagonism to mobilize iron and to treat anemia
Study NCT02754167 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo comparator
Study NCT01010321 — intervention group
Intervention type: DEVICE
Intervention: confocal microscopy
Description: non-invasive imaging
Study NCT01692431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: High fat meal containing EPA
Study NCT01692431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: High fat meal containing DHA
Study NCT01692431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: High fat meal containing negligible EPA/DHA content
Study NCT02277639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACs device
Description: Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
Study NCT00831922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 3 mg/kg/day
Study NCT00831922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: 6 mg/kg/day
Study NCT04075383 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate dental implant
Description: Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
Study NCT03789422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association of levocetirizine and tranexamic acid
Description: levocetirizine 10 mg/day + tranexamic acid 2 g/day
Study NCT03789422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine only
Description: levocetirizine 20 mg/day
Study NCT00412087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D3)
Description: randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
Study NCT04075383 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate-delayed dental implant
Description: Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
Study NCT03446079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Anti Aging Cream
Description: Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
Study NCT00412087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
Study NCT00412087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
Study NCT03827629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study NCT03827629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Naloxone Nasal Spray
Description: Participants received naloxone nasal spray following a 10 hour fast.
Study NCT04395885 — intervention group
Intervention type: OTHER
Intervention: Electronic questionnaire
Description: Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
Study NCT02236364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour, Bayer Healthcare, LLC
Description: Blood glucose measurement
Study NCT03827629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Naloxone HCL Intramuscular (IM) Injection
Description: Participants received naloxone HCl IM injection following a 10 hour fast.
Study NCT02192437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur amino acid restricted diet
Description: Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
Study NCT03217045 — intervention group
Intervention type: OTHER
Intervention: nutrition protocol introduction
Description: Growth comparison of 2 cohorts of infants evaluated in a before-after design
Study NCT04389840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.
Study NCT02603159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine(Aibin)
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
Study NCT02603159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine(Aibin)
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
Study NCT02603159 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study NCT02603159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study NCT04389840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline
Study NCT03321981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenocutuzumab
Description: full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
Study NCT03321981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: humanised IgG1 monoclonal antibody
Study NCT03321981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: antineoplastic drug of vinca alkaloid family
Study NCT03321981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: same endocrine therapy is administered as the last line of endocrine therapy
Study NCT03524222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Hospitalization
Description: See above
Study NCT01022814 — intervention group
Intervention type: DEVICE
Intervention: A disposable pad containing sensitive chemical indicators
Description: After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
Study NCT02221583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astagraf XL
Description: Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
Study NCT02221583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
Study NCT02221583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
Study NCT04098471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal local excision following radiotherapy
Description: transanal local excision following radiotherapy
Study NCT01592708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic anesthesia protocol
Description: Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
Study NCT02962830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: intra-amniotic injection of 10 micrograms of Sufentanil
Study NCT00856583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
Study NCT00856583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
Study NCT02418325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Description: Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
Study NCT02062450 — intervention group
Intervention type: DEVICE
Intervention: Primary surgery with Dual Mobility Cup
Description: Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
Study NCT02062450 — intervention group
Intervention type: DEVICE
Intervention: Revision surgery with Dual Mobility Cup
Description: Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
Study NCT02730910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Crackers
Description: Whole grain crackers manufactured with purple wheat
Study NCT02730910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Granola Bars
Description: Whole grain granola bars manufactured with purple wheat
Study NCT02418325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study NCT06535724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection
Description: 1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery.
Study NCT03020420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatricell Cream
Description: Cream to be applied 2 times a day for 8weeks to 6 months
Study NCT02706522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allocated to Carbohydrated group
Description: Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
Study NCT02706522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Allocated to Placebo group
Description: Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
Study NCT00690924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Oral
Study NCT00690924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study NCT00690924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study NCT03023891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg tablet once
Study NCT04223102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue collection
Description: A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from >5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
Study NCT02579993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pannus and conjunctival dissection
Description: A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
Study NCT02579993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human cultivated limbal stem cell transplantation
Description: The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
Study NCT02093299 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: a blood sample is drawn on all patients to determine responder status